(Q35045060)

English

Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

0 references

neurodegeneration

1 reference

based on heuristic

inferred from title

movement disorders

1 reference

based on heuristic

inferred from title

author name string

Jia Liu

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Lu-ning Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

28

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

63-68

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Mitochondrial approaches for neuroprotection

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Creatine and cyclocreatine attenuate MPTP neurotoxicity

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

The effects of idebenone on mitochondrial bioenergetics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Mutations in COQ2 in familial and sporadic multiple-system atrophy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Pharmacotherapy for Friedreich ataxia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

A controlled trial of idebenone in Huntington's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Coenzyme Q10 deficiency in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

8OHdG is not a biomarker for Huntington disease state or progression

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

The Interaction of Q Analogs, Particularly Hydroxydecyl Benzoquinone (Idebenone), with the Respiratory Complexes of Heart Mitochondria

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0124-4

21 January 2018

Serum levels of coenzyme Q10 in patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24242074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24242074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24242074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24242074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/24242074

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-013-0124-4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35045060&oldid=2197187957"